Investor's Business Daily on MSN
Travere is on a crash course with its 200-day line — here's what happened
Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug, ...
Q3 earnings swing to loss as revenue rises Travere Therapeutics (TVTX) just delivered third quarter 2026 numbers that pulled investor attention to both sides of the income statement. Revenue reached ...
Management reiterated the long-term FILSPARI goal rather than issuing quarterly EPS or revenue guidance: Dr. Dube said results and demand trends “are aligned with our long-term goals of achieving $3 ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Monday reported a loss of $52.3 million in its third ...
Revenue reached $224.6 million versus $164.9 million a year earlier. HARMONY topline results are anticipated in the second half of 2027.
Travere Therapeutics’ Q3 2026 U.S. net product sales rose approximately 95% to $220.2 million, led by 120% growth in FILSPARI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results